102. Rubinstein-Taybi syndrome Clinical trials / Disease details
Clinical trials : 3 / Drugs : 5 - (DrugBank : 1) / Drug target genes : 7 - Drug target pathways : 17
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01619644 (ClinicalTrials.gov) | April 2012 | 12/6/2012 | Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial | Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial | Rubinstein-Taybi Syndrome | Drug: sodium valproate;Drug: Placebo | University Hospital, Bordeaux | Fondation Syndrome de Rubinstein-Taybi | Completed | 6 Years | 21 Years | Both | 41 | Phase 2 | France |